Does a carrier keep its advantages after becoming a gel?

An attractive story with a missing link

A carrier retains more active material under light. A finished formulation produces greater membrane recovery. It is tempting to join these results into a single story: better stability, slower release and therefore a better product. But the experiments have not established every link.

The shikonin study first investigated nanostructured lipid carriers, or NLCs, then incorporated them into a hyaluronic-acid/carboxymethyl-cellulose (HA/CMC) hydrogel patch. The useful question is what each measurement allows us to conclude, rather than whether the study is valuable.

Three measurements, not one verdict

Under the study's light conditions, the shikonin NLCs retained more shikonin than the solution. A separate dialysis experiment found slower release. Lipid protection is an explanation offered by the authors; the experiment did not isolate every possible cause.

The gel experiment asked a different question. At 24 hours, more shikonin was recovered from Strat-M membrane extracts than with the solution, while none was detected in the receptor fluid. This does not by itself show that gel formation slowed release. Release, membrane retention, surface residue, detection limits and extraction recovery can all affect the readings.

The one-month gel assessment mainly covered appearance, pH, weight, thickness and adhesion. These physical observations do not substitute for intact-shikonin quantification or a matched test of whether the carrier's light-retention advantage survives gel formation.

Three measurements, three questions

Original measurement concept, not experimental data. These endpoints do not answer one another.

The CBD comparison sharpens the question

In the CBD-extract NLC study, MCT and oleic-acid systems retained more CBD after light exposure than the Transcutol P system at fixed P188, but released less over 24 hours. Greater retention and faster release did not point in the same direction.

This is not a replication of the shikonin study. The material contained 87% CBD rather than being pure CBD; active materials, lipids and light sources differed. The Strat-M experiment with Tween 20 in the receptor fluid cannot be pooled with the shikonin dialysis experiment.

The studies offer complementary methods evidence, not a direct ranking. The hydrogel review adds a materials perspective: natural, synthetic and hybrid gels differ, and natural-source materials can vary between batches. It is not a third independent efficacy experiment.

The CBD paper is included for academic comparison of carriers and measurement methods. Cannabidiol is prohibited as an ingredient in cosmetics in China. This discussion is not a recommendation to use it in Chinese cosmetic formulations; applying the methods to other compliant materials requires new validation.

What is the strongest competing explanation?

The carrier may protect the target material and the gel may support local retention. If local deposition is the intended goal, a low receptor-fluid reading is not automatically undesirable.

Alternatively, partitioning, adsorption or extraction recovery may change the reading without increasing effective exposure at the target location. Higher intact-material retention alone does not prove greater function.

Light absorption, sample thickness, temperature and recovery are further possibilities. Several explanations may coexist. A lower recovered concentration in a gel is not sufficient evidence that its network disrupted a protective mechanism.

Keep competing explanations in view

Competing explanations, not established mechanisms.

What could Muzi test first?

For cosmetic development in China, select a compliant target material, one target formulation and a single material batch. Compare free and encapsulated material with and without gel, with suitable empty-carrier and vehicle controls. Match measured intact-target dose, not just commercial ingredient percentage.

For light exposure, record illumination, temperature, thickness and exposure geometry. Check analytical selectivity and matrix recovery. Separately measure surface residue, membrane extracts and receptor fluid, including total recovery and detection capability.

Then test independently prepared batches and relevant process changes. Shelf-life, local exposure and skin feel are separate customer requirements. These are proposed experiments, not measurements already performed by Muzi.

Our prediction, and what would change it

Muzi's conditional prediction is that selecting carriers by encapsulation efficiency or a single light test will become insufficient when customers require intact-material retention, target exposure and batch reproducibility together. A material combined with a target formulation and a reproducible measurement method may become a more useful offering. This is an adoption hypothesis, not a market trend proven by these papers.

Matched experiments showing a reproducible retention advantage in the gel without a meaningful loss of target exposure would strengthen the transferability hypothesis. If dose, vehicle controls, partitioning or recovery explain the difference, the carrier-specific attribution should narrow.

Without adequate precision, independent batches and relevant conditions, the question remains open. Non-significance is not equivalence. The useful outcome is knowing what to measure next and what would make us change the explanation, not declaring that encapsulation always works.

What would change our judgment?

Proposed decision criteria, not completed measurements or numerical forecasts.